Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

This phase II, open-label, single-group fixed-order study evaluates feasibility, safety and antidepressant effects of inhaled N,N‑Dimethyltryptamine (DMT) in patients with partial response to depression treatment.

Participants receive up to two inhaled DMT doses in one day (15 mg then 60 mg, ~1 hour apart) delivered via a vapour device; outcomes include acute and subacute mood measures and safety assessments with cardiovascular and respiratory exclusions applied.